Strides Pharma Science Limited is an Indian pharmaceutical company, headquartered in Bangalore. The company is engaged in the development and manufacturing of pharmaceutical products, over-the-counter drugs, and nutraceuticals. Strides Pharma Science Ltd's pharmaceutical products are sold in over 100 countries globally.
The company's core competence lies in the development and manufacture of a wide range of niche and technically complex pharmaceutical products. Strides Pharma Science is also recognized as one of the world's largest manufacturers of soft gelatin capsules. It has established itself as a significant player in the global pharmaceutical industry through its focused approach on developing and manufacturing IP-led niche finished dosage formulations.
Strides Pharma Science operates through two primary business verticals: Regulated Markets and Emerging Markets. Its manufacturing footprint spans 8 facilities across 4 continents, including 5 US FDA-approved facilities. The company also boasts a dedicated R&D facility in India with global filing capabilities. The manufacturing capabilities cover a diverse array of dosage forms, including soft and hard gelatin capsules, tablets, oral liquids, powders, topicals, ointments, creams, sachets, semi-solids, modified-release products, liquids, nasal sprays, and gels.
The company has a presence of 15 manufacturing sites across six countries and a marketing presence in 50 countries. Strides partners with generic companies to supply retail and hospital generics, particularly in injectable products and softgels. This extensive global footprint enables Strides to serve both highly regulated markets such as the United States and Europe, as well as emerging markets across Asia, Africa, and Latin America.
The generic pharma business is driven by IP-based product licensing and global marketing and distribution partnerships. The company specializes in manufacturing niche generic formulations across various dosage forms, including tablets, capsules, liquids, and sachets, with a strong focus on regulated markets such as the United States, Europe, and Australia.
Strides Pharma Science has maintained its competitive advantage through strategic acquisitions and partnerships over the years. The company has consistently pursued an inorganic growth strategy, which has led to its foray into new markets, the addition of new business segments, therapeutic areas, and manufacturing infrastructure. This strategic approach has enabled Strides to systematically expand its therapeutic portfolio and geographic reach.
Strides Pharma Science boasts a market capitalization of ₹8,097 Crore, showing a significant increase of 98.6% in the last year. The company reported a revenue of ₹4,565 Crore and a profit of ₹3,598 Crore. The stock is currently trading at 3.17 times its book value. While the company has delivered a sales growth of 10.6% over the past five years, recent quarterly performance has been exceptional.
In the quarter ended March 2025, Strides Pharma Science's net profit rose by 352.09% to ₹82.19 Crore, compared to ₹18.18 Crore in the corresponding quarter of the previous year (March 2024). Sales increased by 14.08% to ₹1,190.39 Crore in the quarter ended March 2025, up from ₹1,043.50 Crore in the previous year.
For the full financial year 2025, the company reported a net profit of ₹3,593.46 Crore, a significant turnaround from a net loss of ₹70.62 Crore in the previous year (FY24). Sales grew by 17.36% to ₹4,565.34 Crore in FY25, compared to ₹3,890.13 Crore in FY24.
- Market Cap: ₹8,097 Crore (as of recent data)
- Revenue (FY25): ₹4,565 Crore
- Net Profit (FY25): ₹3,593 Crore
- Q4 FY25 Revenue: ₹1,190 Crore
- Q4 FY25 Net Profit: ₹82.19 Crore
- Promoter Holding: 28.30% (as of Mar 2025)
The company's consistent commitment to quality has provided a significant competitive advantage in a rapidly evolving regulatory landscape. Quality interventions, supported by an IT-driven platform, have enabled the implementation of advanced quality standards across all manufacturing locations. Strides maintains a dedicated R&D facility in India with global filing capabilities, which facilitates the development of products for both domestic and international markets.
With a robust pipeline of over 150 Abbreviated New Drug Applications (ANDAs) and significant potential in the controlled substance nasal spray segment, management is optimistic about future expansion in the US market. This strong pipeline positions the company well for continued growth in the highly regulated US market.
Strides Pharma Science has been actively expanding its product portfolio through strategic acquisitions. The cumulative market size for the acquired portfolio is approximately $57 million (as per IQVIA data from 2025). The total consideration for the acquisition of these ANDAs is $2.075 million (₹17.6 Crore). These acquisitions include products in therapeutic segments for treating infections, pain management, allergy symptoms, and attention deficit disorders.
The Board of Directors of Strides Pharma Science, at its meeting held on May 22, 2025, recommended a final dividend of ₹4 per equity share (40%), subject to shareholder approval. This demonstrates the company's commitment to returning value to its shareholders.
Currently, 100% of analysts recommend a 'BUY' rating for Strides Pharma Science Ltd. The company's strong performance has been reflected in its stock price, with the share price moving up by 90.51% on BSE in the Last 12 Months and by 394.83% on BSE over the Last 3 Years.
Strides Pharma Science Limited remains optimistic about its growth prospects in the US market, maintaining a sales target of $400 million for FY28. This indicates strong confidence in the company's future growth trajectory. The company's focus on niche and technically complex pharmaceutical products, combined with its extensive global manufacturing footprint and robust regulatory compliance, positions it well for sustained growth in the competitive pharmaceutical industry.
